Sandbox ap: Difference between revisions

Latest revision as of 16:03, 16 May 2018

==Classification Gastritis

Gastritis		Etiology	Gasstritis synonyms
Non-atrophic		Helicobacter pylori Other factors	Superficial Diffuse antral gastritis (DAG) Chronic antral gastritis (CAG) Interstitial - follicular Hypersecretory Type B*
Atrophic	Autoimmune	Autoimmunity	Type A* Diffuse corporal Pernicious anemia-associated
	Multifocal atrophic	Helicobacter pylori	Type B, type AB
		Dietary	Environmental
		Environmental factors	Metaplastic
Special form	Chemical	Chemical irritation	Reactive
		Bile	Reflux
		NSAIDs	NSAID
		Other agents	Type C*
	Radiation	Radiation injury

Risk assessment table

Scoring criteria for risk assessment*
Scoring system	Score	Risk
IMPROVEDD Score^[1]		Predicted % VTE risk through 42 days
	0	0.4%
	1	0.6%
	2	0.8%
	3	1.2%
	4	1.6%
	5-10	2.2%
		Predicted % VTE risk through 77 days
	0	0.5%
	1	0.7%
	2	1.0%
	3	1.4%
	4	1.9%
	5-10	2.75
IMPROVE score^[2]		Predicted % VTE risk through 3 months
	0	0.5%
	1	1.0%
	2	1.7%
	3	3.1%
	4	4%
	5-8	11%
Padua Score^[3]	< 4	Low risk for VTE
Padua Score^[3]	≥ 4	High risk for VTE
Caprini score^[4]	0-1	Low risk of VTE
	2	Moderate of VTE
	3-4	High risk of VTE
	≥ 5	Highest risk for VTE

Images ILD

Cellular Players and Molecules in IPF
Adapted from European Respiratory Review

Flow Chart for Lung Fibrosis Evaluation in ILD
Adapted from Clinics in Chest Medicine

Widget

Tweets by NEJM!

Tweets by NEJM

References

↑ . doi:10.1055/s-0037-160392910.1055/s-0037-1603929. Missing or empty |title= (help)
↑ Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.
↑ Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M; et al. (2010). "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score". J Thromb Haemost. 8 (11): 2450–7. doi:10.1111/j.1538-7836.2010.04044.x. PMID 20738765.
↑ Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F (1991). "Clinical assessment of venous thromboembolic risk in surgical patients". Semin Thromb Hemost. 17 Suppl 3: 304–12. PMID 1754886.

[1] . doi:10.1055/s-0037-160392910.1055/s-0037-1603929. Missing or empty |title= (help)

[pmid21436241-2] Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.

[pmid20738765-3] Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M; et al. (2010). "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score". J Thromb Haemost. 8 (11): 2450–7. doi:10.1111/j.1538-7836.2010.04044.x. PMID 20738765.

[pmid1754886-4] Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F (1991). "Clinical assessment of venous thromboembolic risk in surgical patients". Semin Thromb Hemost. 17 Suppl 3: 304–12. PMID 1754886.

[1]

[2]

[3]

[4]

@@ Line 155: / Line 155: @@
 |}
-==Pathophysiology of ILD==
+==Images ILD==
+<gallery widths=200px>
-<div style="text-align: center;">'''Algorithm showing pathophysiology of Interstitial Lung Disease'''</div>
+F2.large.jpg | Cellular Players and Molecules in IPF <br> [http://err.ersjournals.com/content/24/135/102.full<font size="-2">''Adapted from European Respiratory Review''</font>]
+</gallery>
+<gallery widths=200px>
-{{Family tree/start}}
+-s2.0-S0272523112000044-gr6.jpg | Flow Chart for Lung Fibrosis Evaluation in ILD <br> [http://http://www.sciencedirect.com/science/article/pii/S0272523112000044/ <font size="-2">''Adapted from Clinics in Chest Medicine''</font>]
-{{Family tree| | | | | | | | | | | | | | | | | | | | | | | T01 | | | | | | | | | | | | T01=[[Tissue]] injury in [[lungs]]}}
-{{Family tree| | | | | | | | | | | | | | | | | |,|-|-|-|-|-|^|-|-|-|-|-|.| | | | | | | | }}
+</gallery>
-{{Family tree| | | | | | | | | | | | | | | | | S01 | | | | | | | | | | S02 | | | | | | | S01=[[Epitehelial]] injury|S02=[[Vascular]] injury}}
-{{Family tree| | | | | | | | | | | | | | | | | |!| | | | | | | | | | | |!| | | | | | | | }}
+==Widget==
-{{Family tree| | | | | | | | R01 | | | | | | | |!| | | | | | | | | | | R02 | | | | | | | R01=[[Mast cell]]s in [[lungs]]|R02= LPA6, LPA2, and LPA4 receptors }}
-{{Family tree| | | | | | |,|-|^|-|.| | | | | | |!| | | | | | | | | |,|-|^|-|.| | | | | | }}
-{{Family tree| | Q01 | | Q06 | | Q03 | | | | | Q02 | | | | | | | | Q04 | | Q05 | | | | | Q01=Decreased [[Secreted frizzled-related protein 1|sFRP-1 (secreted frizzled-related protein 1)]] in [[fibroblasts]]|Q02= [[Insulin-like growth factor]] ([[IGF]]) signalling|Q03=[[Transforming growth factor-β]] ([[TGF-β]])|Q04= Reduced expression of angiogenic factors,<br>[[vascular endothelial growth factor]] (VEGF)|Q05=Elevation of angiostatic factors,<br>pigment epithelium-derived factor|Q06=Secretes [[tryptase]]}}
+<div class="nomobile">
-{{Family tree| | |!| | | |!| | | |!| | | |,|-|-|^|-|-|.| | | | | | |`|-|v|-|'| | | | | | }}
+<div style="position:right; width:50%; float:right; background-color:#d0d0d0; border-radius: 10px;"><span style="position:right; float:right; width: 100%;"><center>'''Tweets by NEJM!'''<hr>{{#Widget:NEJM}}</center>
-{{Family tree| | P01 | | P02 | | P05 | | P04 | | | | P03 |.| | | | | | P06 | | | | | P01=[[Wnt signaling pathway|Wnt/β-catenin signalling pathway]]|P02=PAR-2/protein kinase (PK)C-α/Raf-1/p44/42 signaling pathway|P03=[[IGFBP3|IGF-binding protein 3 (IGFBP3|IGFBP-3]])|P04=[[Insulin-like growth factor binding protein|IGF-binding protein 5 (IGFBP-5)]]|P05=Upregulation of Egr-1 (early growth response protein 1)|P06=Loss of [[endothelial]] barrier function }}
+</span></div>
-{{Family tree| |!| |!| | |!| | | |!| | | |!| | | | | |!| |!| | | | | | |!| | | | | | | | }}
+</div>
-{{Family tree| O01 |!| | |!| | | |`|-|-|-|^|.| | | | |!| O02 | | | | | |!| | | | | | | | O01=Dysregulation of repair in [[lung tissue]]  and activation of [[fibroblasts]]|O02=Regulates [[transforming growth factor-β]] ([[TGF-β]]) }}
-{{Family tree| | | |!| | |!| | | | | | | | |!| | | | |!|,|'| | | | | | |!| | | | | | | | }}
+<br style="clear:right" />
-{{Family tree| | | |!| | |!| | | | | | | | |!| | | | A02 | | | | | | | |!| | | | | | | | A01=|A02=Induction of syndecan-2 (SDC2)}}
-{{Family tree| | | |!| | |!| | | | | | | | |!| | | | |!| | | | | | | | |!| | | | | | | | }}
-{{Family tree| | | |!| | |`|-|-|-|-|-|-|-|.|!|,|-|-|-|'| | | | | | | | |!| | | | | | | | }}
-{{Family tree| | | |`|-|-|-|-|-|-|-|-|-|-| B01 | | | | | | | | | | | | |!| | | | | | | | B01=Activation,proliferation, and migration of [[fibroblast]] to the site of injury}}
-{{Family tree| | | | | | | | | | | | | | | |!| | | | | | | | | | | | | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | | | | C01 | | | | | | | | | | | | |!| | | | | | | | C01=[[Fibroblasts]]}}
-{{Family tree| | | | | | | | | | | | |,|-|-|+|-|-|.| | | | | | | | | | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | D01 | |!| | D02 | | | | | | | | | |!| | | | | | | | D01=Altered PTEN (phosphatase and tensin homologue)/Akt axis|D02=Acquire contractile stress fibres}}
-{{Family tree| | | | | | | | | | | | |!| | |!| | |!| | | | | | | | | | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | G01 | |!| | G02 | | G03 | | | | | |!| | | | | | | | G01= Inactivates [[FOX proteins|Fox (forkhead box) O3a]]|G02=Protomyofibroblast, composed of cytoplasmic [[actins]]|G03=[[Pleural]] [[mesothelial]] cells (PMCs)}}
-{{Family tree| | | | | | | | | | | | |!| | |!| | |!| | | |!| | | | | | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | H01 | |!| | H02 | | H03 | | | | | |!| | | | | | | | H01= Downregulation of [[Caveolin 1|caveolin-1 (cav-1)]] and Fas expression|H02=De novo expression of α-smooth muscle actin (α-SMA)|H03=TGF-β1-dependent mesothelial–mesenchymal transition}}
-{{Family tree| | | | | | | | | | | | |!| | |!| | | |!| |!| | | | | | | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | I01 | |!| | | | I02 | | | | | | | |!| | | | | | | | I01=[[Fibroblast]] resistant to [[apoptosis]]|I02=[[Myofibroblasts]]}}
-{{Family tree| | | | | | | | | | | | | | | |!| | | |!| |!| | | | | | | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | | | | |!| | | |!| |)|-|-|-|-|.| | |!| | | | | | | | }}
-{{Family tree| | | | | | | | | | | | | | | |!| | | |!| J02 | | | J03 | |!| | | | | | | | J02=Different ranges of contractions mediated by RhoA/Rho-associated kinase|J03=Changes in intracellular calcium concentrations}}
-{{Family tree| | | | | | | | | | | | | | | |!| | | |!| | |`|-|v|-|'| | |!| | | | | | | | }}
-{{Family tree| | | | | | | | K01 | | | | | |!| |,|-|'| | | | K02 | | | |!| | | | | K03 | K01=Recruitement of fibrocytes in [[lungs]]|K02=Lock step mechanism of cyclic and contractile events|K03=[[T helper cell|T-helper cell type 2]] on site of injury}}
-{{Family tree| | | | | | | | |!| | | | | | |!| |!| | | | | | |!| | | | |!| | | | | |!| | }}
-{{Family tree| | | | | | | | L01 | | | | | | L02 | | | | | | L03 | | | |!| | | | | L04 | |L01=Upregulation of [[CXCR4|C-X-C chemokine receptor type 4 (CXCR4)]]<br>on [[fibrocytes]] and its ligand<br>CXCL12 (stromal cell-derived factor 1)|L02=Excess extracellular matrix production|L03=Exerting traction force|L04=[[Interleukin-13]]}}
-{{Family tree| | | | | | | | |!| | | | | | | |!|,|-|-|-|-|-|-|'| | | | |!| | | | | |!| | }}
-{{Family tree| | | | | | | | M01 | | | | | | M02 | | | | | | | | | | | |!| | | | | M03 | |M01=Migration of fibrocytes to the site of injury|M02=Tissue remodelling|M03=Alternate pathway activation of [[macrophages]]}}
-{{Family tree| | | | | | | | |!| | | | | | | |!| | | | | | | | | | | | |!| | | | | |!| | }}
-{{Family tree| | | | | | | | |`|-|-|-|-|-|-|.|!|,|-|-|-|-|-|-|-|-|-|-|-|'| | | | | |!| | }}
-{{Family tree| | | | | | | | | | | | | | | | N01 |-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|'| N01=Lung Fibrosis}}
-{{Family tree/end}}
 ==References==
-<references />

Sandbox ap: Difference between revisions

Latest revision as of 16:03, 16 May 2018

Contents

==Classification Gastritis

Risk assessment table

Images ILD

Widget

References

Navigation menu